Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
81 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016', provides in depth analysis on Smoothened Homolog (Protein Gx or SMO) targeted pipeline therapeutics. The report provides comprehensive information on the Smoothened Homolog (Protein Gx or SMO) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO) - The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects - The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Smoothened Homolog (Protein Gx or SMO) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Smoothened Homolog (Protein Gx or SMO) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential ands scope
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Smoothened Homolog (Protein Gx or SMO) Overview 7 Therapeutics Development 8 Smoothened Homolog (Protein Gx or SMO) - Products under Development by Stage of Development 8 Smoothened Homolog (Protein Gx or SMO) - Products under Development by Therapy Area 9 Smoothened Homolog (Protein Gx or SMO) - Products under Development by Indication 10 Smoothened Homolog (Protein Gx or SMO) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Smoothened Homolog (Protein Gx or SMO) - Products under Development by Companies 14 Smoothened Homolog (Protein Gx or SMO) - Products under Development by Universities/Institutes 17 Smoothened Homolog (Protein Gx or SMO) - Therapeutics Assessment 19 Assessment by Monotherapy/Combination Products 19 Assessment by Mechanism of Action 20 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Smoothened Homolog (Protein Gx or SMO) - Companies Involved in Therapeutics Development 25 BeiGene Ltd 25 F. Hoffmann-La Roche Ltd 26 Ignyta Inc 27 IMPACT Therapeutics Inc 28 Mayne Pharma Group Ltd 29 Novartis AG 30 PellePharm Inc 31 Pfizer Inc 32 Redx Pharma Plc 33 Stemline Therapeutics Inc 34 Smoothened Homolog (Protein Gx or SMO) - Drug Profiles 35 glasdegib - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 GSA-10 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 IMP-5471 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 itraconazole - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Monoclonal Antibody to Inhibit Smoothened for Oncology - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 patidegib hydrochloride - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 RDX-001 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Small Molecules to Antagonize Smoothened (Smo) Receptor for Oncology - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Small Molecules to Inhibit Smoothened Homolog for Oncology - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 sonidegib phosphate - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 taladegib - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 vismodegib - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Smoothened Homolog (Protein Gx or SMO) - Dormant Projects 61 Smoothened Homolog (Protein Gx or SMO) - Discontinued Products 65 Smoothened Homolog (Protein Gx or SMO) - Featured News & Press Releases 66 Dec 08, 2016: PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome 66 Dec 03, 2016: New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome 67 Nov 28, 2016: Curis Announces Full Approval of Roche's Erivedge® in the European Union 68 Oct 20, 2016: HedgePath Pharmaceuticals Announces Further Positive Interim Data in its Phase II(b) Cancer Trial 68 Aug 03, 2016: HedgePath Pharmaceuticals Announces Positive Interim Data in its Phase II(b) Cancer Trial 69 Jun 02, 2016: Curis Announces Presentations Related to Erivedge at 2016 ASCO Annual Meeting 70 Jun 02, 2016: FDA Grants Orphan Drug Designation to SUBA-Itraconazole for Treatment of Patients with BCCNS 71 Sep 29, 2015: HedgePath Pharmaceuticals Announces Commencement of Patient Treatment in its Phase II(b) Clinical Trial 71 Aug 21, 2015: HedgePath Pharmaceuticals Launches Clinical Trial for its Proposed Cancer Treatment 72 Aug 20, 2015: Novartis drug Odomzo gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients 73 Jul 24, 2015: FDA approves Novartis drug Odomzo (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer 74 May 20, 2015: Curis Announces Presentations of Erivedge Clinical Data at 2015 ASCO Annual Meeting 75 May 18, 2015: New Equity Investment In Hedgepath Pharmaceuticals Ahead Of Commencing Phase IIB Trial With Suba-Itraconazole In Skin Cancer 76 Mar 09, 2015: Skin tumors develop specific mutations to resist drug, researchers say 76 Mar 02, 2015: Basal Cell Carcinoma Drug Encourages Both Cancer Regression and Loss of Taste in Patients 78 Appendix 80 Methodology 80 Coverage 80 Secondary Research 80 Primary Research 80 Expert Panel Validation 80 Contact Us 80 Disclaimer 81
List of Tables Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Early Stage Products, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Development by Companies, H2 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H2 2016 17 Products under Investigation by Universities/Institutes, H2 2016 18 Assessment by Monotherapy/Combination Products, H2 2016 19 Number of Products by Stage and Mechanism of Action, H2 2016 20 Number of Products by Stage and Route of Administration, H2 2016 22 Number of Products by Stage and Molecule Type, H2 2016 24 Pipeline by BeiGene Ltd, H2 2016 25 Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 26 Pipeline by Ignyta Inc, H2 2016 27 Pipeline by IMPACT Therapeutics Inc, H2 2016 28 Pipeline by Mayne Pharma Group Ltd, H2 2016 29 Pipeline by Novartis AG, H2 2016 30 Pipeline by PellePharm Inc, H2 2016 31 Pipeline by Pfizer Inc, H2 2016 32 Pipeline by Redx Pharma Plc, H2 2016 33 Pipeline by Stemline Therapeutics Inc, H2 2016 34 Dormant Projects, H2 2016 61 Dormant Projects (Contd..1), H2 2016 62 Dormant Projects (Contd..2), H2 2016 63 Dormant Projects (Contd..3), H2 2016 64 Discontinued Products, H2 2016 65
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
